Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Arrowhead Pharmaceuticals Inc

Healthcare US ARWR

73.09USD
-2.07(2.75%)

Last update at 2026-06-05T20:00:00Z

Day Range

72.0975.43
LowHigh

52 Week Range

12.4476.76
LowHigh

Fundamentals

  • Previous Close 75.16
  • Market Cap9949.29M
  • Volume1227764
  • P/E Ratio43.32
  • Dividend Yield-%
  • EBITDA325.65M
  • Revenue TTM1090.98M
  • Revenue Per Share TTM7.97
  • Gross Profit TTM 1090.98M
  • Diluted EPS TTM1.64

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax 51.53M -612.46000M -206.49100M -172.70900M -140.84600M
Minority interest -31.74500M 10.20M 4.00M -0.43100M -
Net income -1.63100M -599.49300M -205.27500M -176.49400M -140.84800M
Selling general administrative 123.94M 96.82M 92.55M 124.43M 80.98M
Selling and marketing expenses - 1.94M - - -
Gross profit 805.52M -15.04400M 240.74M 243.23M 138.29M
Reconciled depreciation 23.93M 18.59M 12.49M 10.42M 8.27M
Ebit 140.89M -580.10800M -200.65800M -188.92800M -149.03600M
Ebitda 164.82M -561.51300M -188.16500M -178.50700M -140.76900M
Depreciation and amortization 23.93M 18.59M 12.49M 10.42M 8.27M
Non operating income net other - - - 0.77M 2.07M
Operating income 98.35M -601.08000M -205.00200M -178.50700M -149.03600M
Other operating expenses 731.10M 604.63M 445.74M 421.74M 287.32M
Interest expense 89.36M 32.35M 18.33M 5.03M 6.12M
Tax provision 21.42M -2.76700M 2.78M 3.79M 0.00200M
Interest income 37.29M 22.72M 15.30M - -
Net interest income -52.07200M -9.63200M -3.02700M 5.03M 6.12M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 21.42M -2.76700M 2.78M 3.79M 0.00200M
Total revenue 829.45M 3.55M 240.74M 243.23M 138.29M
Total operating expenses 707.17M 586.04M 445.74M 421.74M 287.32M
Cost of revenue 23.93M 18.59M - - -
Total other income expense net -46.81300M -11.38000M 1.54M 5.80M 8.19M
Discontinued operations - - - - -
Net income from continuing ops 30.11M -609.69300M -209.27500M -172.70900M -140.84800M
Net income applicable to common shares - - - -176.06300M -140.84800M
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 1385.30M 1139.80M 765.55M 691.94M 710.15M
Intangible assets 6.86M 8.56M 10.26M 11.96M 13.66M
Earning assets - - - - -
Other current assets 24.45M 14.51M 7.08M 20.20M 2.19M
Total liab 881.88M 948.74M 478.39M 585.98M 301.33M
Total stockholder equity 466.05M 185.44M 271.34M 105.96M 408.82M
Deferred long term liab - - - - -
Other current liab 128.12M 85.44M -46.42900M -5.64400M 23.77M
Common stock 0.23M 0.22M 0.20M 105.96M 0.20M
Capital stock 0.23M 0.22M 0.20M 105.96M 0.20M
Retained earnings -1627.15400M -1625.52300M -1026.03000M -820.75500M -644.69200M
Other liab - - - 55.95M 190.27M
Good will - - - - -
Other assets - - - 0.22M 96.76M
Cash 226.55M 102.69M 110.89M 108.00M 184.43M
Cash and equivalents - - - - -
Total current liabilities 195.49M 103.17M 0.87M 74.10M 146.54M
Current deferred revenue 2.40M - 0.87M 74.10M 111.06M
Net debt 139.74M 14.68M 4.28M -26.42900M -158.88900M
Short term debt 47.29M 6.34M 10.56M 2.78M 2.25M
Short long term debt 40.00M - - - -
Short long term debt total 366.28M 117.37M 115.17M 81.58M 25.55M
Other stockholder equity 2086.53M 1806.00M 1300.39M 820.89M 1053.39M
Property plant equipment - - - 110.30M 48.67M
Total current assets 950.64M 695.47M 110.89M 376.40M 384.60M
Long term investments - - 292.74M 105.87M 245.59M
Net tangible assets - - - 398.52M 395.16M
Short term investments 692.82M 578.28M 292.74M 268.39M 183.35M
Net receivables 6.82M - 0.00000M 1.41M 10.26M
Long term debt 214.88M 393.18M - - -
Inventory - - - -21.61400M 4.36M
Accounts payable 17.67M 11.39M 35.87M 2.87M 9.46M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - 19.82M -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 6.44M 4.75M -3.22200M -0.13600M -0.06900M
Additional paid in capital - - - - -
Common stock total equity - - - 0.20M 0.20M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -820.75500M -644.69200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.39M 4.48M 361.93M 29.12M 0.27M
Deferred long term asset charges - - - - -
Non current assets total 434.66M 444.33M 654.66M 315.54M 325.55M
Capital lease obligations 111.40M 117.37M 115.17M 81.58M 25.55M
Long term debt total - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments -129.29400M -420.07200M -96.15500M 47.36M -118.11100M
Change to liabilities - - - 11.23M 13.38M
Total cashflows from investing activities -129.29400M -420.07200M - -5.41700M -141.67800M
Net borrowings -191.36500M 392.00M - - -
Total cash from financing activities 74.01M 870.52M 253.05M 65.19M 11.30M
Change to operating activities - - - 11.95M 10.39M
Net income 30.11M -609.69300M -209.27500M -176.49400M -140.84800M
Change in cash 123.86M -8.20600M 2.89M -76.42900M 40.85M
Begin period cash flow 102.69M 110.89M 108.00M 184.43M 143.58M
End period cash flow 226.55M 102.69M 110.89M 108.00M 184.43M
Total cash from operating activities 179.55M -462.85100M -153.89000M -136.13100M 171.22M
Issuance of capital stock 241.39M 429.26M - 0.00000M 0.00000M
Depreciation 23.93M 18.59M 12.49M 10.42M 8.27M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - -3.36200M - 9.16M
Change to account receivables -56.96700M 0.00000M 1.41M 8.85M -9.40900M
Sale purchase of stock - - - 5.19M 11.30M
Other cashflows from financing activities -5.00000M 46.87M 253.05M 60.00M 11.30M
Change to netincome - - - 125.33M 76.67M
Capital expenditures 22.67M 141.47M 176.74M 52.78M 23.57M
Change receivables - - - 8.85M -9.40900M
Cash flows other operating - - - -118.36400M 222.90M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -76.36200M 40.85M
Change in working capital -18.23500M 25.09M -51.54700M -98.29300M 226.87M
Stock based compensation 63.37M 73.97M 78.13M 120.89M 76.67M
Other non cash items 80.38M 29.19M 50.72M 7.34M 0.27M
Free cash flow 156.89M -604.32000M -330.62700M -188.90800M 147.66M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ARWR
Arrowhead Pharmaceuticals Inc		 -2.07 2.75% 73.09 43.32 111.11 9.12 17.50 8.57 25.24
NVO
Novo Nordisk A/S		 -0.79 1.81% 42.96 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.6937 1.57% 43.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 5.09 1.15% 446.83 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.72 1.07% 635.45 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Arrowhead Pharmaceuticals Inc

177 East Colorado Boulevard, Pasadena, CA, United States, 91105

Key Executives

Name Title Year Born
Dr. Christopher R. Anzalone Ph.D. CEO, Pres & Director 1969
Mr. Kenneth A. Myszkowski Chief Financial Officer 1966
Mr. Patrick O'Brien J.D., PharmD COO & Gen. Counsel 1964
Dr. James C. Hamilton M.D., MBA Sr. VP of Discovery & Translational Medicine 1979
Dr. Javier San Martin M.D. Chief Medical Officer 1965
Dr. Mark M. Davis Ph.D. Founder and Founder & Director of Insert Therapeutics Inc & Calando NA
Dr. Vincent Anzalone CFA Head of Investor Relations & VP NA
Mr. Howard Lovy Director of Communications NA
Dr. Mark Seefeld Head of Toxicology & VP 1954
Ms. Tracie Oliver Chief Commercial Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.